Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model

• Published in: Cancer letters 2016-08, Vol.379 (1), p.117-123
• Main Authors: Evans, Angharad, Jamieson, Stephen M.F, Liu, Dong-Xu, Wilson, William R, Perry, Jo K
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents, Hormonal - pharmacology; Binding sites; Cancer therapies; Cell growth; Cell Line, Tumor; Cell Proliferation - drug effects; Chemoradiotherapy; Deoxyribonucleic acid; DNA; DNA damage; Endometrial cancer; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - metabolism; Endometrial Neoplasms - pathology; Endometrial Neoplasms - radiotherapy; FDA approval; Female; Growth hormone; Growth hormones; Health sciences; Hematology, Oncology and Palliative Medicine; Hormone Antagonists - pharmacology; Human Growth Hormone - analogs & derivatives; Human Growth Hormone - pharmacology; Humans; Insulin-Like Growth Factor I - metabolism; Medical prognosis; Mice; Mitogen-Activated Protein Kinases - metabolism; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - prevention & control; Pegvisomant; Radiation; Radiation therapy; Radiation-Sensitizing Agents - pharmacology; Receptors, Somatotropin - antagonists & inhibitors; Receptors, Somatotropin - metabolism; RL95-2; Rodents; Signal transduction; Signal Transduction - drug effects; Studies; Time Factors; Tumor Hypoxia; Tumors; Xenograft; Xenograft Model Antitumor Assays
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2016.05.031

Highlights • The GH receptor is a potential target for anticancer therapy. • We demonstrate that pegvisomant combined with radiation significantly delayed the regrowth of RL95-2 xenografts. • Pegvisomant also decreased the area of CD31 labelling in unirradiated tumours. • Blockade of the human GH receptor may improve the response of GH and/or IGF1-responsive tumours to radiation.